IL150634A0 - 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs - Google Patents

4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs

Info

Publication number
IL150634A0
IL150634A0 IL15063401A IL15063401A IL150634A0 IL 150634 A0 IL150634 A0 IL 150634A0 IL 15063401 A IL15063401 A IL 15063401A IL 15063401 A IL15063401 A IL 15063401A IL 150634 A0 IL150634 A0 IL 150634A0
Authority
IL
Israel
Prior art keywords
tetrahydroisoquinol
methanesulfonamido
polymorphs
dimethoxy
pyridyl
Prior art date
Application number
IL15063401A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005200A external-priority patent/GB0005200D0/en
Priority claimed from GB0015900A external-priority patent/GB0015900D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of IL150634A0 publication Critical patent/IL150634A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
IL15063401A 2000-03-03 2001-02-23 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs IL150634A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005200A GB0005200D0 (en) 2000-03-03 2000-03-03 New salt form
GB0015900A GB0015900D0 (en) 2000-06-28 2000-06-28 New salt form
PCT/IB2001/000244 WO2001064672A1 (en) 2000-03-03 2001-02-23 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs

Publications (1)

Publication Number Publication Date
IL150634A0 true IL150634A0 (en) 2003-02-12

Family

ID=26243792

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15063401A IL150634A0 (en) 2000-03-03 2001-02-23 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs

Country Status (40)

Country Link
US (1) US6683085B2 (xx)
EP (1) EP1268468B1 (xx)
JP (1) JP3857919B2 (xx)
KR (1) KR100496089B1 (xx)
CN (1) CN1214029C (xx)
AP (1) AP2002002611A0 (xx)
AR (1) AR029482A1 (xx)
AT (1) ATE253570T1 (xx)
AU (1) AU779118B2 (xx)
BG (1) BG106869A (xx)
BR (1) BR0108910A (xx)
CA (1) CA2398963C (xx)
CR (1) CR6731A (xx)
CZ (1) CZ20022858A3 (xx)
DE (1) DE60101157T2 (xx)
DK (1) DK1268468T3 (xx)
EA (1) EA004748B1 (xx)
EE (1) EE200200496A (xx)
ES (1) ES2208565T3 (xx)
GE (1) GEP20043364B (xx)
HK (1) HK1053655A1 (xx)
HN (1) HN2001000036A (xx)
HR (1) HRP20020718A2 (xx)
HU (1) HUP0300006A3 (xx)
IL (1) IL150634A0 (xx)
IS (1) IS6441A (xx)
MA (1) MA26876A1 (xx)
MX (1) MXPA02008665A (xx)
NO (1) NO20024195L (xx)
NZ (1) NZ519672A (xx)
OA (1) OA12186A (xx)
PE (1) PE20011225A1 (xx)
PL (1) PL365070A1 (xx)
PT (1) PT1268468E (xx)
SI (1) SI1268468T1 (xx)
SK (1) SK12282002A3 (xx)
TN (1) TNSN01034A1 (xx)
TR (1) TR200302130T4 (xx)
UA (1) UA72311C2 (xx)
WO (1) WO2001064672A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
DE10223913A1 (de) * 2002-05-29 2003-12-11 Bayer Cropscience Ag Verfahren zur Herstellung spezifischer Kristallmodifikationen polymorpher Substanzen
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914114A (en) 1984-05-28 1990-04-03 Merck Patent Gesellschaft Mit Breschrankter Haftung 3-[4-(4-phenyl-1,2,3,6-tetrahydro-1-pyridyl)butyl]-5-hydroxy-indole methanesulfonate having sedating and anti-parkinsonism properties
AU594512B2 (en) * 1986-09-16 1990-03-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Hydroxy indole derivatives
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
SI1268468T1 (en) 2004-04-30
WO2001064672A1 (en) 2001-09-07
IS6441A (is) 2002-06-25
CR6731A (es) 2004-03-11
TR200302130T4 (tr) 2004-01-21
US6683085B2 (en) 2004-01-27
AU779118B2 (en) 2005-01-06
ES2208565T3 (es) 2004-06-16
NZ519672A (en) 2004-06-25
DE60101157T2 (de) 2004-09-02
TNSN01034A1 (fr) 2005-11-10
EE200200496A (et) 2004-02-16
UA72311C2 (uk) 2005-02-15
EP1268468B1 (en) 2003-11-05
DK1268468T3 (da) 2004-02-09
AR029482A1 (es) 2003-07-02
CA2398963A1 (en) 2001-09-07
CN1214029C (zh) 2005-08-10
KR100496089B1 (ko) 2005-06-17
BG106869A (bg) 2002-12-29
AP2002002611A0 (en) 2002-09-30
HUP0300006A2 (en) 2003-05-28
US20020010188A1 (en) 2002-01-24
DE60101157D1 (de) 2003-12-11
NO20024195D0 (no) 2002-09-03
JP2003525289A (ja) 2003-08-26
EP1268468A1 (en) 2003-01-02
PE20011225A1 (es) 2001-12-08
CN1432010A (zh) 2003-07-23
AU3588801A (en) 2001-09-12
KR20020080463A (ko) 2002-10-23
GEP20043364B (en) 2004-03-10
MA26876A1 (fr) 2004-12-20
BR0108910A (pt) 2002-12-24
CZ20022858A3 (cs) 2003-09-17
EA200200826A1 (ru) 2003-02-27
CA2398963C (en) 2006-10-24
PL365070A1 (en) 2004-12-27
SK12282002A3 (sk) 2003-10-07
NO20024195L (no) 2002-09-03
ATE253570T1 (de) 2003-11-15
HK1053655A1 (en) 2003-10-31
OA12186A (en) 2006-05-09
JP3857919B2 (ja) 2006-12-13
PT1268468E (pt) 2004-01-30
EA004748B1 (ru) 2004-08-26
HRP20020718A2 (en) 2004-02-29
MXPA02008665A (es) 2003-02-24
HN2001000036A (es) 2001-07-09
HUP0300006A3 (en) 2006-01-30

Similar Documents

Publication Publication Date Title
MXPA03006121A (es) Terapia de combinacion usando inhibidores del receptor tirosin-cinasa e inhibidores de la angiogenesis.
PL370480A1 (en) Aminopyrimidines and pyridines
DK1341774T3 (da) Kondenserede heteroaromatiske glucokinase-aktivatorer
IL158669A0 (en) Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
HUP0300205A3 (en) Aurora 2 kinase inhibitor quinazoline derivatives, preparation and use thereof
IS6524A (is) 5-alkýlpyrídó(3-3-D)pyrimídín týrósín kínasa tálmar
AU2002238042A1 (en) Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
IS2399B (is) Aðferðir til að framleiða 2-(N-metýl-N-metansúlfónýlamínó)pýrimidín, hýdroxýpýrimidín, halógenpýrimidín eða lífrænar súlfónýloxýpýrimidín afleiður ogefnasambönd sem fást með þeim
DK1480983T3 (da) Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
GC0000151A (en) 2-(3,5-Bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-o-tolyl-pyridin-3-yl)-isobutyramide.
IL150634A0 (en) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs
MXPA03004136A (es) Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy).
HUP0600064A2 (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
HK1062683A1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(E)-=-methyloxime and its salts.
ZA200207409B (en) Drilling and anchor setting arrangement.
HK1061392A1 (en) 5-'4-'2-(N-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione mesylate salt
AU2002256260A1 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas